PROTOX CLEARED TO START PROSTATE CANCER TRIAL

Protox has received FDA clearance to proceed with a Phase I clinical trial of a novel investigational cancer drug aimed at recurrent prostate cancer.

The trial will study the drug PRX302, which is the first of a class of drugs, referred to as targeted prodrugs, based on engineered protein toxins. The drug is an inactive prodrug that is injected into the prostate where it turns into a potent cell-killing toxin when it comes in contact with prostate-specific antigen-producing cells.